Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hironori Harada

Showing results (1-10 of 112) with videos related to

Pageof 12
Sort By:
International Journal of Hematology|April 28, 2017
Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspectsHironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 19, 2007
[Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations]Hironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2011
[Molecular pathogenesis of MDS]Hironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2017
MDS: Recent progress in molecular pathogenesis and clinical aspectsHironori Harada
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 9, 2012
[Therapy-related myeloid neoplasms]Yuka Harada, Hironori Harada
Cancer Science|January 23, 2015
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapiesHironori Harada, Yuka Harada
Cancer Science|April 7, 2023
Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disordersYoshihiro Hayashi, Hironori Harada
Journal of Cellular Biochemistry|January 27, 2011
Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutationsYuka Harada, Hironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 9, 2013
[Acute promyelocytic leukemia]Yuka Harada, Hironori Harada
Journal of Cellular Physiology|April 1, 2009
Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutationsYuka Harada, Hironori Harada
Pageof 12

Showing results (1-10 of 112) with videos related to

Sort By:
Pageof 12
International Journal of Hematology|April 28, 2017
Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspectsHironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|August 19, 2007
[Distinct genetic pathway in the molecular pathogenesis of MDS/AML with AML1/RUNX1 point mutations]Hironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2011
[Molecular pathogenesis of MDS]Hironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|October 6, 2017
MDS: Recent progress in molecular pathogenesis and clinical aspectsHironori Harada
Nihon Rinsho. Japanese Journal of Clinical Medicine|November 9, 2012
[Therapy-related myeloid neoplasms]Yuka Harada, Hironori Harada
Cancer Science|January 23, 2015
Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapiesHironori Harada, Yuka Harada
Cancer Science|April 7, 2023
Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disordersYoshihiro Hayashi, Hironori Harada
Journal of Cellular Biochemistry|January 27, 2011
Molecular mechanisms that produce secondary MDS/AML by RUNX1/AML1 point mutationsYuka Harada, Hironori Harada
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 9, 2013
[Acute promyelocytic leukemia]Yuka Harada, Hironori Harada
Journal of Cellular Physiology|April 1, 2009
Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutationsYuka Harada, Hironori Harada
Pageof 12